Literature DB >> 20697074

Technology evolution: is it survival of the fittest?

Anthony Zietman1, Michael Goitein, Joel E Tepper.   

Abstract

New technologies are constantly being developed and introduced into medical practice. Their potential or actual use raises questions of efficacy and cost. All too often financial considerations of profit primarily determine whether a technology will be adopted. In an era in which the need to control costs has become clear, this situation is undesirable. The assessment of efficacy can, however, be very difficult, and the control of financial aspects is likewise problematic. In this article, we address these problems and suggest potential solutions, using proton radiotherapy as an example that may be relevant to the development of other medical devices.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697074     DOI: 10.1200/JCO.2010.29.4645

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  When to wait for more evidence? Real options analysis in proton therapy.

Authors:  Janneke P C Grutters; Keith R Abrams; Dirk de Ruysscher; Madelon Pijls-Johannesma; Hans J M Peters; Eric Beutner; Philippe Lambin; Manuela A Joore
Journal:  Oncologist       Date:  2011-12-06

Review 2.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

Review 3.  Promise and pitfalls of heavy-particle therapy.

Authors:  Timur Mitin; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 4.  Proton beam and prostate cancer: An evolving debate.

Authors:  Anthony Zietman
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-03

5.  Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida.

Authors:  Florian R Schroeck; John M Hollingsworth; Samuel R Kaufman; Brent K Hollenbeck; John T Wei
Journal:  Urology       Date:  2012-07-27       Impact factor: 2.649

6.  Technology diffusion and diagnostic testing for prostate cancer.

Authors:  Florian R Schroeck; Samuel R Kaufman; Bruce L Jacobs; Ted A Skolarus; David C Miller; Alon Z Weizer; Jeffrey S Montgomery; John T Wei; Vahakn B Shahinian; Brent K Hollenbeck
Journal:  J Urol       Date:  2013-05-10       Impact factor: 7.450

7.  Strategic level proton therapy patient admission planning: a Markov decision process modeling approach.

Authors:  Ridvan Gedik; Shengfan Zhang; Chase Rainwater
Journal:  Health Care Manag Sci       Date:  2016-01-25

8.  The impact of technology diffusion on treatment for prostate cancer.

Authors:  Florian R Schroeck; Samuel R Kaufman; Bruce L Jacobs; Yun Zhang; Alon Z Weizer; Jeffrey S Montgomery; Scott M Gilbert; Seth A Strope; Brent K Hollenbeck
Journal:  Med Care       Date:  2013-12       Impact factor: 2.983

9.  Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer.

Authors:  Nikhil G Thaker; David Boyce-Fappiano; Matthew S Ning; Dario Pasalic; Alexis Guzman; Grace Smith; Emma B Holliday; James Incalcaterra; Adam S Garden; Simona F Shaitelman; G Brandon Gunn; C David Fuller; Pierre Blanchard; Thomas W Feeley; Robert S Kaplan; Steven J Frank
Journal:  Int J Part Ther       Date:  2021-06-25

Review 10.  Proton beam therapy and localised prostate cancer: current status and controversies.

Authors:  J A Efstathiou; P J Gray; A L Zietman
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.